ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc.

Michael Thornton co-founded ENDRA Life Sciences in 2009, spinning the company out of academic research at the University of Michigan. The firm took its name from 'end' and 'radiology,' reflecting its mission to replace invasive tissue biopsies with non-invasive ultrasound-based measurements. Thornton has led the firm through multiple funding rounds, including an IPO on the TSX Venture Exchange in 2015 under the ticker ENDR. ENDRA's core product is the TAEUS system, which combines radio-frequency energy with ultrasound to quantify liver fat — a key biomarker in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The device received FDA clearance for liver fat measurement in 2021. The 2021 pivotal trial reported 93% sensitivity and 95% specificity versus biopsy as gold standard. ENDRA targets a market of approximately 100 million NAFLD patients in the US alone, with the global NASH diagnostics market projected at $40B by 2030. As of 2024, ENDRA remains a development-stage commercial company with limited revenue. The firm had raised approximately $30M in financing from its 2015 IPO through early 2024, including a February 2024 public offering of common stock and warrants that grossed $2.9M (per SEC filing, February 2024). Operating expenses in 2023 were approximately $8.3M. The company had cash and equivalents of roughly $600K as of year-end 2023, requiring additional capital to fund commercial scaling. ENDRA's structural position is unusual: it is a publicly traded medical device developer rather than a family office or asset manager. The firm maintains its HQ in Ann Arbor, Michigan, near its academic roots at the University of Michigan. No information suggests this operates as a family office or wealth management entity. Its primary asset class is medical device intellectual property, not financial capital deployment.